The von Hippel-Lindau (VHL) mutation, which is widely recognized as an essential contributor for the pathogenesis of ccRCC, was reported to arise in up to 90% of patients with ccRCC 2, 8. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.